• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接种减毒活呼吸道合胞病毒疫苗的小鼠中,被动获得的抗体可抑制体液免疫,但不能抑制细胞介导的免疫。

Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.

作者信息

Crowe J E, Firestone C Y, Murphy B R

机构信息

Department of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, 1161 21st Avenue S., Nashville, TN 37232, USA.

出版信息

J Immunol. 2001 Oct 1;167(7):3910-8. doi: 10.4049/jimmunol.167.7.3910.

DOI:10.4049/jimmunol.167.7.3910
PMID:11564809
Abstract

A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age to protect young infants; therefore, it will need to be effective in the presence of maternally acquired RSV Abs. In the present study, the immunogenicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation were evaluated in mice passively immunized with varying quantities of RSV Abs. The replication of the RSV vaccines was suppressed in the lower, but not the upper, respiratory tract of the passively immunized mice. Immunization with either vaccine candidate was highly efficacious against challenge with wild-type RSV in both passively immunized and control mice. Nonetheless, a high level of immunity was seen even in passively/actively immunized animals that failed to develop a humoral immune response, suggesting that T cells mediated the immunity. Depletion of CD4+ and CD8+ T cells in passively/actively immunized and control animals at the time of challenge with wild-type RSV demonstrated that CD4+ and CD8+ T cells made significant independent contributions to the restriction of replication of RSV challenge virus in both the upper and lower respiratory tracts. Although passively acquired serum RSV Abs suppressed the primary systemic and mucosal Ab responses of IgM, IgG, and IgA isotypes, B lymphocytes were nevertheless primed for robust secondary Ab responses. Thus, immunity mediated by CD4+ and CD8+ T cells and Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic levels of RSV neutralizing Abs.

摘要

呼吸道合胞病毒(RSV)疫苗需要在1月龄前接种以保护幼儿;因此,它需要在存在母体获得的RSV抗体的情况下发挥作用。在本研究中,在被动免疫了不同数量RSV抗体的小鼠中评估了两种不同减毒水平的减毒活RSV候选疫苗的免疫原性和效力。RSV疫苗的复制在被动免疫小鼠的下呼吸道而非上呼吸道中受到抑制。两种候选疫苗免疫均对被动免疫小鼠和对照小鼠的野生型RSV攻击具有高效力。尽管如此,即使在未能产生体液免疫反应的被动/主动免疫动物中也观察到高水平的免疫力,这表明T细胞介导了免疫。在用野生型RSV攻击时,对被动/主动免疫和对照动物的CD4+和CD8+ T细胞进行耗竭,结果表明CD4+和CD8+ T细胞对上、下呼吸道中RSV攻击病毒复制的限制均做出了显著的独立贡献。尽管被动获得的血清RSV抗体抑制了IgM、IgG和IgA同种型的原发性全身和粘膜抗体反应,但B淋巴细胞仍被激发以产生强烈的继发性抗体反应。因此,在存在生理水平RSV中和抗体的情况下,活RSV候选疫苗可在小鼠中轻易诱导由CD4+和CD8+ T细胞及抗体介导的免疫。

相似文献

1
Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines.在接种减毒活呼吸道合胞病毒疫苗的小鼠中,被动获得的抗体可抑制体液免疫,但不能抑制细胞介导的免疫。
J Immunol. 2001 Oct 1;167(7):3910-8. doi: 10.4049/jimmunol.167.7.3910.
2
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.一种新型的呼吸道合胞病毒(RSV)F亚基疫苗,佐以GLA-SE,在啮齿动物模型中引发了强大的保护性TH1型体液免疫和细胞免疫。
PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.
3
Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.呼吸道合胞病毒融合蛋白亚单位候选疫苗在老年小鼠与年轻小鼠中的免疫原性和效力较低。
PLoS One. 2017 Nov 28;12(11):e0188708. doi: 10.1371/journal.pone.0188708. eCollection 2017.
4
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.利用基于宿主范围减毒的牛副流感病毒3型载体骨架的活cDNA衍生疫苗对恒河猴进行针对呼吸道合胞病毒A和B亚组以及人副流感病毒3型的黏膜免疫。
J Virol. 2002 Feb;76(3):1089-99. doi: 10.1128/jvi.76.3.1089-1099.2002.
5
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.鼻腔内用含单磷酰脂质 A 的病毒体呼吸道合胞病毒疫苗在小鼠和棉鼠中的疗效和安全性。
Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13.
6
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.用甲醛灭活的呼吸道合胞病毒(RSV)免疫BALB/c小鼠,然后对其进行RSV攻击所诱导的肺部组织病理学变化,可通过清除CD4+ T细胞而消除。
J Virol. 1992 Dec;66(12):7444-51. doi: 10.1128/JVI.66.12.7444-7451.1992.
7
Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.缺失小疏水基因的呼吸道合胞病毒部分减毒与白细胞介素-1β反应升高有关。
J Virol. 2015 Sep;89(17):8974-81. doi: 10.1128/JVI.01070-15. Epub 2015 Jun 17.
8
Intranasal respiratory syncytial virus vaccine attenuated by codon-pair deoptimization of seven open reading frames is genetically stable and elicits mucosal and systemic immunity and protection against challenge virus replication in hamsters.通过对 7 个开放阅读框的密码子对进行去优化而减毒的鼻腔内呼吸合胞病毒疫苗具有遗传稳定性,并能诱导黏膜和系统免疫,以及防止仓鼠受到挑战病毒复制的侵害。
PLoS Pathog. 2024 May 13;20(5):e1012198. doi: 10.1371/journal.ppat.1012198. eCollection 2024 May.
9
A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.一种表达呼吸道合胞病毒(RSV)F或G蛋白的单剂量重组副流感病毒5载体疫苗可保护棉鼠和非洲绿猴免受RSV攻击。
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.
10
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.表达呼吸道合胞病毒(RSV)融合蛋白的重组低血清流行率腺病毒载体Ad26和Ad35可诱导棉鼠对RSV感染产生保护性免疫。
Vaccine. 2015 Oct 5;33(41):5406-5414. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.

引用本文的文献

1
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment.中和单克隆抗体治疗后的长期抗SARS-CoV-2抗体轨迹。
PLoS One. 2025 Jun 18;20(6):e0325561. doi: 10.1371/journal.pone.0325561. eCollection 2025.
2
Antibody feedback regulation.抗体反馈调节
Immunol Rev. 2024 Nov;328(1):126-142. doi: 10.1111/imr.13377. Epub 2024 Aug 23.
3
Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review.接受抗新型冠状病毒肺炎单克隆抗体治疗的患者对严重急性呼吸综合征冠状病毒2的内源性抗体反应:一项系统评价。
Clin Immunol Commun. 2022 Dec;2:106-109. doi: 10.1016/j.clicom.2022.08.003. Epub 2022 Aug 27.
4
Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus.重塑我们的认知:在理解人类呼吸道合胞病毒免疫反应方面取得的进展
Pathogens. 2023 Sep 1;12(9):1118. doi: 10.3390/pathogens12091118.
5
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.接受REGN-COV2治疗的新冠病毒感染个体的内源性抗体反应。
Oxf Open Immunol. 2023 Jan 6;4(1):iqac012. doi: 10.1093/oxfimm/iqac012. eCollection 2023.
6
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial.新冠康复者恢复期血浆治疗住院患者的疗效与安全性——一项开放标签的II期临床试验
Life (Basel). 2022 Oct 9;12(10):1565. doi: 10.3390/life12101565.
7
Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.单克隆抗体治疗对内源性 SARS-CoV-2 抗体应答的影响。
Clin Immunol. 2022 Mar;236:108959. doi: 10.1016/j.clim.2022.108959. Epub 2022 Feb 24.
8
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的出现及恢复期血浆疗法在感染管理中的作用
Life (Basel). 2021 Jul 23;11(8):734. doi: 10.3390/life11080734.
9
Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019.2019年重症冠状病毒病患者高滴度恢复期血浆的特征及输注后的抗体动力学
Open Forum Infect Dis. 2021 Jul 16;8(8):ofab385. doi: 10.1093/ofid/ofab385. eCollection 2021 Aug.
10
Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的先天免疫介导的抗病毒反应以及康复期血清:一种应对2019冠状病毒病(COVID-19)的潜在预防和治疗剂
Antib Ther. 2020 Aug 16;3(3):212-220. doi: 10.1093/abt/tbaa019. eCollection 2020 Jul.